News

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 45^th Annual Growth Stock Conference on Tuesday, June 3^rd, at 10:00 a.m. CT

Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society

Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI^® (encorafenib) in combination with

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% core⁽¹⁾ compared with the

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product

Charles River Laboratories International, Inc. (NYSE: CRL) and CHDI Foundation, Inc., today announced an extension of their ongoing drug discovery partnership into the foreseeable future. The

Agilent Technologies Inc. (NYSE: A) today announced August Specht, Ph.D., has been named the company’s Chief Technology Officer. Specht, previously vice president of Global R&D for the

Regulatory News:

POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM) and reminds

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the William Blair

Agilent Technologies Inc. (NYSE: A) today announced the launch of its latest innovation in liquid chromatography (LC)-mass detection: the Agilent InfinityLab Pro iQ Series. This groundbreaking

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company received an RTF letter from the FDA for

Agilent Technologies Inc. (NYSE: A) today announced the latest enhancements to the Agilent 8850 Gas Chromatograph (GC), including compatibility with single and triple quadrupole mass spectrometry

Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events.

• 
  PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May 31